Mode
Text Size
Log in / Sign up
Phase 1 Completed N=26 Treatment

A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer

Source: ClinicalTrials.gov NCT00958477 ↗
Enrolled (actual)
26
Serious AEs
50.0%
Results posted
Aug 2017
Primary outcomePrimary: Number of Subjects With Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 subjects

Summary

This study is intended to test an experimental new drug called, EMD 525797 (Study Drug). This drug is not yet approved for sale and has only been tested in a small number of people to date (prior to this study starting another research study was carried out involving 37 healthy volunteers receiving the Study Drug). Until more is known about this Study Drug, it can only be used in research studies. This research study is planned to answer important questions about how the Study Drug is tolerated and how it may work in patients with prostate cancer with bone metastases. This is a small study which is expected to include 24 patients, and will be conducted in approximately 3 hospitals in Germany and 1 hospital in Brussels, Belgium. The study will last until the last patient has had their last study visit which is expected to be about 18 months in total.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Subjects With Dose Limiting Toxicity (DLT)
0; 0; 0; 0
PRIMARY
Number of Subjects With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Related TEAEs
8; 6; 6; 6; 5; 1
PRIMARY
Observed Maximum Serum Concentration (Cmax) of EMD 525797 After First Infusion
52.9; 115.5; 298.0; 368.9
PRIMARY
Observed Maximum Serum Concentration (Cmax) of EMD 525797 After Third Infusion
55.7; 130.3; 371.8; 485.7
PRIMARY
Area Under the Serum Concentration-time Curve From Time Zero to the Last Sampling Time (AUC0-t) After First Infusion
3583; 15609; 40080; 50891
PRIMARY
Total Body Clearance of Drug From Serum (CL) After First Infusion
0.060; 0.027; 0.019; 0.020
PRIMARY
Apparent Volume of Distribution During Terminal Phase (Vz) of EMD 525797 After First Infusion
5.06; 4.64; 4.35; 6.16
PRIMARY
Trough Serum Concentration (Ctrough) Of EMD 525797 at Week 1
0.00; 0.00; 0.00; 0.00
PRIMARY
Trough Serum Concentration (Ctrough) Of EMD 525797 at Week 3
0.43; 15.17; 51.16; 81.22
PRIMARY
Trough Serum Concentration (Ctrough) Of EMD 525797 at Week 5
2.70; 27.97; 105.77; 150.74
SECONDARY
Time to Reach Observed Serum Concentration (Tmax) After First Infusion
1.0; 8; 2.0; 2.0
SECONDARY
Time to Reach Observed Serum Concentration (Tmax) After Third Infusion
1; 3; 1; 1
SECONDARY
Number of Subjects With Positive Anti-EMD 525797 Antibodies
0; 0; 0; 0; 4; 0
SECONDARY
Serum Levels of Interleukin 6 (IL-6) and Interleukin 8 (IL-8)
SECONDARY
C-Reactive Protein Levels
SECONDARY
Apparent Terminal Half-life (t1/2) of EMD 525797 After First Infusion
60.3; 109.5; 184.5; 222.1
SECONDARY
Elimination Rate Constant (λz) of EMD 525797 After First Infusion
0.0119; 0.0059; 0.0043; 0.0032
SECONDARY
Observed Minimum Serum Concentration (Cmin) of EMD 525797 After Third Infusion
2.7; 28.0; 102.8; 150.7
SECONDARY
Average Serum Concentration at Steady State (Cav) of EMD 525797 After Third Infusion
16.4; 57.1; 187.2; 178.5
SECONDARY
Area Under the Serum Concentration-time Curve Within One Complete Dosing Interval (AUCtau) of EMD 525797 After First Infusion
4398; 15609; 40080; 50553
SECONDARY
Area Under the Serum Concentration-time Curve Within One Complete Dosing Interval (AUCtau) of EMD 525797 After Third Infusion
6028; 20306; 67160; 85401
SECONDARY
Area Under the Serum Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of EMD 525797 After First Infusion
4152; 18317; 53580; 75408
SECONDARY
Peak Trough Fluctuation Over One Dosing Interval at Steady State (%PTF) of EMD 525797 After Third Infusion
326; 179; 145; 190
SECONDARY
Mean Residence Time of Drug in the Body (MRT) of EMD 525797 After First Infusion
87.2; 171.0; 230.5; 299.9
SECONDARY
Apparent Volume of Distribution at Steady State (Vss) of EMD 525797 After Third Infusion
4.63; 4.35; 3.35; 4.32
SECONDARY
Accumulation Ratio Of Cmax (R_Cmax)
1.10; 1.19; 1.25; 1.32
SECONDARY
Accumulation Ratio of AUC (R_AUC)
1.37; 1.32; 1.68; 1.69
SECONDARY
Number of Subjects With Best Overall Response (BOR)
0; 0; 0; 0; 0; 0
SECONDARY
Progression-free Survival (PFS) as Per Prostate Cancer Clinical Trials Working Group 1 (PCWG1) and Prostate Cancer Clinical Trials Working Group 2 (PCWG2) Criteria
NA; 1.0; 2.3; 7.5; 3.0; 3.4
SECONDARY
Time to Progression (TTP)
1.18; 4.17; 1.28; 2.83; 3.02; 1.18
SECONDARY
Number of Subjects With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score vs. Worst Post-baseline Score
2; 3; 2; 1; 1; 0
SECONDARY
Number of Subjects With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score vs. Best Post-baseline Score
3; 3; 3; 3; 0; 0
SECONDARY
Total Pain Score Using Brief Pain Inventory-Short Form (BPI-sf)
2.32; 1.95; 1.95; 2.52; 1.73; 1.64
SECONDARY
Maximum Percent Change From Baseline in Prostate Specific Antigen (PSA) Level
138.41; 580.32; 120.76; 120.41
SECONDARY
Minimum Percent Change From Baseline in PSA Level
8.69; -9.88; 17.94; -7.72

Eligibility Criteria

Inclusion Criteria

  • Provision of signed written informed consent
  • Age superior or equal to 18 years
  • Subjects with histological or cytologically proven prostate cancer with evidence of bone metastases on bone scans or CT / MRI after prior chemotherapy with e.g. taxane or mitoxantrone Patients should have undergone bilateral orchiectomy or should be on continuous androgen deprivation therapy with a gonadotropin releasing hormone agonist or antagonist and should have stopped any anti-androgen therapy for at least 4 weeks before inclusion in the study. Patients should be either on stable (i.e., since at least 3 months) ongoing therapy with a bisphosphonate or without any bisphosphonate therapy. Initiation of a bisphosphonate therapy within this time period prior the study or during the study is not allowed. Total serum testosterone should be less than 50 ng/dL or 1.7 nmol/L.
  • Evidence of progressive disease, defined by at least two PSA values above the individual nadir level with an increase of at least 10% each determined at a minimum interval of 2 weeks before screening examination. Presence of a measurable lesion is not required for study entry. Nodal (in lymph nodes superior or equal to 2cm) or visceral progression is sufficient for trial entry independent of PSA.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at study entry and an estimated life expectancy of at least 3 months.
  • Adequate hematological function, defined by white blood cell count (WBC) greater than or equal to 3 x 109/L with absolute neutrophil count (ANC) greater than or equal to 1.5 x 109/L, and lymphocyte count greater than or equal to 0.5 x 109/L; platelet count greater than or equal to 100 x 109/L; and hemoglobin greater than or equal to 9 g/dL.
  • Adequate hepatic function defined by total bilirubin level less than or equal to 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels less than or equal to 2.5 x ULN; or, for subjects with documented metastatic disease to the liver, AST and ALT levels less than or equal to 5 x ULN.
  • Adequate renal function defined by serum creatinine less than 1.5 mg/dL.
  • Effective contraception. If the risk of conception exists, pregnancy has to be avoided during the study (SCR to EOS) as well as during at least 3 month after last dosing using an effective contraception method (e.g. double barrier method)

Exclusion Criteria

  • Any systemic cytotoxic cancer treatment within 4 weeks before treatment with EMD 525797.
  • Acute pathologic fracture, spinal cord progression, hypercalcemia (within 4 weeks period prior to screening).
  • Radiotherapy to bone lesions, orthopaedic surgery, or any investigational drug in the 30 days before the start of treatment in this study and during treatment period, and/or biopsies involving bone within 2 weeks before the start of treatment in this study.
  • Supraphysiologic doses of steroids (defined as superior or equal to 7.5 mg of prednisone equivalents per day).
  • Previous treatment with anti-integrin therapy.
  • Confirmed or clinically suspected brain metastases.
  • Known hypersensitivity reactions to any of the components of the study medication.
  • History of allergic reactions to other monoclonal antibody (mAb) therapy.
  • Uncontrolled hypertension (systolic greater or equal to 160 mmHg, diastolic greater than or equal to 100 mmHg).
  • Current history of chronic daily aspirin therapy (ASS at doses inferior or equal to 100 mg is permitted), bleeding disorders and/or history of thromboembolic events (history of superficial thrombophlebitis is not an exclusion criterion); thrombolytics or oral or parenteral anticoagulants within 10 days prior to study start and during treatment period.
  • Severe peripheral vascular disease or ulceration.
  • Unstable angina pectoris, or myocardial infarction within 6 months before start of study treatment, clinical significant abnormal ECG at screening
  • Known alcohol o
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00958477). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search